atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
Company profile
Ticker
ATRC
Exchange
Website
CEO
Michael H. Carrel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AtriCure Europe, B.V. • AtriCure, LLC • SentreHEART LLC • AtriCure Spain, S.L. • AtriCure Germany GmbH • AtriCure UK Limited • AtriCure Canada, Inc. • AtriCure Hong Kong Limited • AtriCure (Beijing) Medicine Information Consulting Service Co., Ltd. • AtriCure Asia Pacific, Ltd. ...
IRS number
341940305
ATRC stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
PRE 14A
Preliminary proxy
20 Mar 24
8-K/A
Departure of Directors or Certain Officers
27 Feb 24
10-K
2023 FY
Annual report
16 Feb 24
8-K
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
15 Feb 24
8-K
Provides Financial Outlook for 2024
8 Jan 24
8-K
AtriCure Appoints Shlomi Nachman to the Board of Directors
4 Jan 24
Transcripts
ATRC
Earnings call transcript
2023 Q4
15 Feb 24
ATRC
Earnings call transcript
2023 Q3
1 Nov 23
ATRC
Earnings call transcript
2023 Q2
25 Jul 23
ATRC
Earnings call transcript
2023 Q1
2 May 23
ATRC
Earnings call transcript
2022 Q4
21 Feb 23
ATRC
Earnings call transcript
2022 Q3
2 Nov 22
ATRC
Earnings call transcript
2022 Q2
3 Aug 22
ATRC
Earnings call transcript
2022 Q1
4 May 22
ATRC
Earnings call transcript
2021 Q4
16 Feb 22
ATRC
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Justin J Noznesky
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Karl S. Dahlquist
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
MICHAEL H CARREL
18 Mar 24
4
Justin J Noznesky
14 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Karl S. Dahlquist
7 Mar 24
4
Deborah Lee Yount
5 Mar 24
4
MICHAEL H CARREL
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 80.60 mm | 80.60 mm | 80.60 mm | 80.60 mm | 80.60 mm | 80.60 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.00 mm | 2.05 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 20.54 mm | 14.00 mm | n/a | n/a |
Cash remaining | n/a | n/a | 60.06 mm | 66.60 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 20.0 | 32.5 | n/a | n/a |
Institutional ownership, Q3 2023
96.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 225 |
Opened positions | 28 |
Closed positions | 24 |
Increased positions | 92 |
Reduced positions | 75 |
13F shares | Current |
---|---|
Total value | 1.95 tn |
Total shares | 46.75 mm |
Total puts | 0.00 |
Total calls | 200.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 4.69 mm | $205.42 bn |
BLK Blackrock | 3.96 mm | $173.39 bn |
Alliancebernstein | 3.23 mm | $141.35 bn |
Champlain Investment Partners | 1.85 mm | $81.10 bn |
Alger Associates | 1.76 mm | $0.00 |
First Light Asset Management | 1.49 mm | $65.24 bn |
MCQEF Macquarie | 1.46 mm | $63.88 bn |
Fred Alger Management | 1.44 mm | $62.89 bn |
Wellington Management | 1.23 mm | $54.03 bn |
STT State Street | 1.15 mm | $50.26 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Justin J Noznesky | Common Stock | Sell | Dispose S | No | Yes | 30.39 | 1,500 | 45.59 k | 72,784 |
18 Mar 24 | Karl S. Dahlquist | Common Stock | Sell | Dispose S | No | Yes | 32.16 | 1,885 | 60.62 k | 50,954 |
14 Mar 24 | Michael H Carrel | Common Stock | Gift | Dispose G | No | No | 0 | 2,000 | 0.00 | 655,532 |
12 Mar 24 | Justin J Noznesky | Common Stock | Sell | Dispose S | No | Yes | 36.72 | 1,500 | 55.08 k | 74,284 |
5 Mar 24 | Karl S. Dahlquist | Common Stock | Sell | Dispose S | No | Yes | 37.36 | 8,231 | 307.51 k | 52,839 |
News
Oppenheimer Upgrades AtriCure to Outperform, Announces $32 Price Target
23 Apr 24
Key Takeaways From AtriCure Analyst Ratings
10 Apr 24
Needham Reiterates Buy on AtriCure, Maintains $46 Price Target
10 Apr 24
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
16 Feb 24
Cracking The Code: Understanding Analyst Reviews For AtriCure
16 Feb 24